

DAFTAR PUSTAKA

1. Pusat data dan informasi. Situasi Penyakit Kanker. Kementerian Kesehatan RI. 2015.
2. Ferlay J. Soerjomataram I. Dikshit R. Eser S. Mathers C. Rebelo M. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. *International Journal of Cancer*. 2015 Mar 1;136(5):359–86.
3. Kwok C. Management of side effects from chemotherapy. *The Hongkong anti cancer society*. 2010;12:201–11
4. Demetri GD. Targeted approaches for the treatment of thrombocytopenia. *The Oncologist*. 2001;6:15–23.
5. Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and Treatment of cancer-related anemia. *Am J Hematol*. 2014;89:203–12.
6. Chinese Society of Clinical Oncology. Experts Committee on Cancer-related Anemia. *Chinese Clinical Oncology*. 2012;11:1–21.
7. Steegmann JL, Sanchez JM, Colomer R, Vaz A, Lopez J, Jalon I, et al. Prevalence and management of anemia in patients with non-myeloid cancer undergoing systemic therapy. a Spanish survey. *Clin Transl Oncol*. 2013. 15:477–83.
8. Schrijvers D, Samblanx HD, Roila F. Erythropoiesis Stimulates agents in the treatment of Anemia in Cancer Patient : ESMO Clinical practice Guidelines for use. *Annals of Oncology*. 2010;1:21–23.
9. Ludwig H, Van BS, Barrett-Lee P, Birgerard G, bokemayer C, Gascon P. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. *Eur J cancer*. 2004;4:2293–306.
10. Xu H, Xu L, Page JH, Cannavale K, Sattayapiwat O, Rodriguez R, et al. Incidence of anemia in patients diagnosed with solid tumour reseiving chemotherapy 2011-2013. *Dovepress*. 2016;8:61–71.
11. Augusti NF. Iron Deficiency in Cancer Patients. *Rev Bras Hematol Hemoler*. 2016;38:325–30.
12. Kirshner j, Hatch M, Hennessy DD, Fridman M, Tannous RE. Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy. *Oncologist*. 2004;9:25–32.

13. Hasegawa I, Tanaka K. Serum Erythropoietin Levels in Gynecologic Cancer Patients during Cisplatin Combination Chemotherapy. *Gynecologic Oncology*. 1992;46(1):65–8.
14. Pedain C, herrero J, kunzel W. Serum Erythropoietin level in ovarian cancer patients receiving chemotherapy. *Eur J Obstet Gynecol Reprod Biol*. 2001 Oct;98(2):224–30.
15. Auerbach M, Ballard H, Trout R, McIlwain M, Ackerman A, Bahrain H, et al. Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial. 2004;4:123–28.
16. Gao L, Ma R, Zhou J, cheng S. Changes of serum Erythropoietin during Cisplatin-or-5-Fluoruracil-Induced Anemia in Rats. *Toxicol Mech Methods*. 2006;16(9):501–6.
17. Feinberg BA, Bruno As, Haislip S, Gilmore J, Jain G, Whyte J. Hemoglobin Trends and Anemia Treatment Resulting From Concomitant Chemotherapy in Community Oncology Clinics. *Journal of Oncology Practice*. 2012;5:18–24.
18. Rizzo JD, Somerfield MR, Hagerly KL, Seidenfeld J, Bohlius J, Bennett CL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. *J Clin Oncol*. 2008;26:132–49.
19. Jerome E. Groopman, Loretta M. Itri. Chemotherapy-Induced Anemia in Adults: Incidence and Treatment. *Journal of the National Cancer Institute*. 2014;91:1616–34.
20. Ziekenhuisnetwerk ma, Antwerp B. Management of Anemia in cancer: transfusion. *the oncologist*. 2011;14:12–18.
21. Mastro L, Venturini M, Strategies for the Use of Epoetin Alfa in Breast Cancer Patients. *The Oncologist*. 1998;3(5):314–18.
22. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. *Br J Cancer*. 2010;102:301–15.
23. Debeljak N, Solar P, Sytkowki AJ. Erythropoietin and cancer : the unintended consequences of Anemia correction. *Frontiers in immunology*. 2014;5:1–13.
24. Arcasoy M, Amin K, Aysen F, Chuan s, Raleigh, Mahesh A et al. Functional significance of Erythropoietin Receptor Expression in Breast Cancer. *Clinical Cancer Research*. 2002;11(1):20–7.

25. Matthew E, Murat O, Arcasoy, Kimberly L, Blackwell, John P et al. Erythropoietin Biology in Cancer. *Clinical Cancer Research*. 2006; 1–9.
26. Fraser JK, Lin FK, Berridge MV: Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, HEL. *Exp Hematol*. 1988;16: 836–42.
27. Widness JA, Schmidt RL, Hohl RJ. Change in erythropoietin pharmacokinetics following hematopoietic transplantation. *Clin Pharmacol Ther*. 2007;81:873–79.
28. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - v.2.2015. Cancer and Treatment-Related Anemia. 2014.
29. Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. *Health Technol Assess*. 2007;11(13):198–02.
30. Piva E, Brugnara C, Chiandetti L, Plebani M. Automated reticulocyte counting: state of the art and clinical applications in the evaluation of erythropoiesis. *Clin Chem Lab Med*. 2010;48(10):1369–80.
31. European Society fo Medical Oncology. Anemia in cancer: ESMO Handbook of Oncological Emergencies; 2016.
32. I Made B. Pendekatan Terhadap Pasien Anemia. Dalam: Setiati S, Alwi I, Sudoyo AW, Stiyohadi B, Syam AF, editor. *Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi VI*. Jakarta : Interna Publishing; 2014.hlm 2575–82.
33. Rinaldi I, Aru W Sudoyo. Anemia Hemolitik Non Autoimun. Dalam: Setiati S, Alwi I, Sudoyo AW, Stiyohadi B, Syam AF, editor. *Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi VI*. Jakarta : Interna Publishing; 2014.hlm 2614–22.
34. Puthenparambil J, Lechner K, Kornek G. Autoimmune hemolytic Anemia as a paraneoplastic phenomenon in solid tumors : A critical Analysis of 52 cases reported in the literature. *Win Klin Wochenschrift*. 2010;122: 229–36.
35. Alberto Z, Barcellini W. Treatment of Autoimmune Hemolytic Anemias. *Hematologica*. 2014;99(10):1547–54.
36. Nazan S, Suar C, Emine Z, Sema A. Management of autoimmune hemolytic anemia in children and adolescents : A single center experience. *Turk J Hematology*. 2011;28:198–205.

37. Kartika W, Elias P. Anemia hemolitik imun. Dalam: Setiati S, Alwi I, Sudoyo AW, Stiyohadi B, Syam AF, editor. Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi VI. Jakarta : Interna Publishing; 2014.hlm 2607–13.
38. Hubert S, Tim H, Hans J, Britta H, Werner L, Alexander R. Aplastic Anemia – Diagnostics and Therapy of Acquired Aplastic Anemia. Onkopedia guidelines. 2012.
39. Widjanarko A, Sudoyo A.W, Solonder H. Anemia Aplastik. Dalam: Setiati S, Alwi I, Sudoyo AW, Stiyohadi B, Syam AF, editor. Buku Ajar Ilmu Penyakit Dalam Jilid II Edisi VI. Jakarta : Interna Publishing; 2014.hlm 2646–56.
40. Hoffbrand AV, Moss PA. Aplastic Anemia. In Essensial Haematology 6th edition. 2011;269–76.
41. Paquette R, Munker R. Aplastic Anemias. In: Munker R, Hiller E, et al (eds). Modern Hematology Biology and Clinical Management 2nd ed. New Jersey: Humana Press. 2007;207–16.
42. Young NS. Aplastic anemia, myelodysplasia, and related bone marrow failure syndromes. In: Kasper DL, Fauci AS, et al (eds). Harrison's Principle of Internal Medicine. 16th ed. New York: McGraw Hill. 2007;617–25.
43. Ludwig H. Iron Metabolism and Iron Supplementation in Cancer patients. wiener klinische Wochenschrift. 2015;907–19.
44. Zhang Caigo ZF. Iron Homeostasis and Tumorigenesis : molecular mechanism and therapeutic opportunities. Protein Cell. 2014;88–100.
45. Saba HI. Anemia in cancer patients: introduction and overview. www.moffitt.usf.edu/pubs/ccj/v5ns/toc.html. 2004.
46. Rouli N, Amalia P. Anemia pada Penyakit Keganasan. Sari Pediatri, Vol. 6, No. 4, Maret 2005: 176–81.
47. Rodgers GM, Becher PS, Blinder M, Cella D, Khan AC, Cleeland C. Cancer- and Chemotherapy-Induced Anemia. National Comprehensive Cancer network. 2012;10: 628–35.
48. Fiedler K, Brunner C. Mechanism controlling hematopoiesis. Hematology Science and practice. 2012;12:1–45.
49. Bull BS. Morphology of the erythron. In: Lichtman MA, Beutler E, Seligsohn U, Kaushansky K, Kipps TO (eds). Williams hematology. 16th ed. USA: New York. McGraw-Hill Medical. 2007;369–86.

50. Dessypris EN, Sawyer ST. Erythropoiesis. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA et al. (eds). *Wintrobe's clinical hematology*. 12th ed. Philadelphia: Lippincott Williams & Wilkins. 2009;106–21.
51. Prchal JT. Production of erythrocytes. In: Lichtman MA, Beutler E, Seligsohn U, Kaushansky K, Kipps TO (eds). *Williams hematology*. 7th ed. USA: New York. McGraw-Hill Medical. 2007;393–04.
52. Morceau F, Dicato M, Diederich M. Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis. *Mediator Inflamm*. 2009;1–11.
53. Escobar MC, Rappaport ES, Tipton P, Balentine P. Reticulocyte estimate from peripheral blood smear: a simple, fast, and economical method for evaluation of anemia. *Laboratory Medicine*. 2002;33:703–05.
54. Riley RS, Ben-Ezra JM, Tidwell Ann. Reticulocyte enumeration: past & present. *Laboratory Medicine*. 2001;32:599–08.
55. Farrel F, Lee A. The Erythropoietin Receptor and Its Expression in Tumor Cells and Other Tissues. *The Oncologist*. 2004;9:18–30.
56. Prenggono MD. Eritropoetin dan Penggunaan Eritropoetin pada Pasien Kanker dengan Anemia. *CDK-224/ vol. 42 no. 1,2015*.
57. Semenza GL. Targeting HIF-1 for cancer therapy. *Nature Rev Cancer*. 2003;3:721–32.
58. Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. *J Clin Oncol*. 2006;24:4708–13.
59. Jelkmann W. Erythropoietin: Structure, control of production, and function. *Physiol Rev*. 1992;72:449–89.
60. Stockman C, Fandrey J. Hypoxia-induced erythropoietin production: A paradigm for oxygen-regulated gene expression. *Clin Exp Pharmacol Physiol*. 2006;33:968–79.
61. Sasaki R, Masuda S, Nagao M. Erythropoietin: Multiple physiological functions and regulation of biosynthesis. *Biosci Biotechnol Biochem*. 2000;64:1775–93.
62. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. *Cell Death Differ*. 2004;11:S37–44.

63. Brines M, Patel NSA, Villa P, Brines C, Mennini T, De Paola M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. *Proc Natl Acad Sci USA*. 2008;105:10925–30.
64. Fisher JW. Erythropoietin: Physiology and pharmacology update. *Exp Biol Med* (Maywood). 2003;228:1–14.
65. Sawyer ST, Penta K. Association of JAK2 and STAT5 with erythropoietin receptors. Role of receptor phosphorylation in erythropoietin signal transduction. *J Biol Chem*. 1996;271(50):32430–7.
66. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, et al. Jak2 is essential for signaling through a variety of cytokine receptors. *Cell*. 1998;93:385–95.
67. Fiedler K, Brunner C. Mechanism controlling hematopoiesis. *Hematology Science and practice*. 2012:1–45.
68. Warr MR, Pietras EM, Passegue E. Mechanism controlling hematopoietic stem cell function during normal hematopoiesis and hematological malignancies. *Jhons wiley & sons*. 2011:681–01.
69. Pinheiro D, Sunkel C. Mechanism of cell cycle control. *Fevereiro*. 2012:1–16.
70. Bhel C, Ziegler C. Cell cycle: the life cycle of a cell. *Molecular mechanism and implications for disease*. 2014:9–19.
71. Morgan G. Chemotherapy and the cell cycle. *Clinical*. 2007:27–30.
72. Goldwein JW, Vachani C. Chemotherapy: the basics. *Cancer resources for patient and healthcare professional*. 2014. Available from URL: <http://www.oncolink.org/treatment/article.cfm?c=142&id=319>. Accessed November 14, 2014.
73. Dahlan MS. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. *Salemba Medika*. 2013:36–80.
74. Family L, Xu L, Xu H, Cannavale K, Sattayapiwat O, Page JO, et al. The effect of chemotherapy-induced anemia on dose reduction and dose delay. *Support Care Cancer*. 2016;24(10):4263–71.
75. Kaminski A, Joseph D, Elsaleh H. Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer. *Australian radiology*. 2007;51:283–88.
76. Ferrari S, Palmerini E, Staals E, Abate ME, Longhi A, Cesari M, et al. sex and age related chemotherapy toxicity in patients non metastatic osteosarcoma. *Journal of chemotherapy*. 2009;21:205–10.

77. Henk VDB, Paulussen M, Teuff GL, Judson I, Genderblom H, Dirksen U. Impact of gender on efficacy and acute toxicity of alkylating agent based chemotherapy in ewing sarcoma. *European J of Cancer*. 2015;51:2453–64.
78. Sabine OP, Vera RZ. Sex and gender aspects in clinical medicine. Springer. 2012:165–68.
79. Kumar J, reccia I, Kusano T, Agrawal S. A Systematic Review on the Erythropoietin Receptors Expression in Various Cancers and Importance of Recombinant Erythropoietin in Chemotherapy Induced Anaemia. *Hematol Transfus Int J*. 2017:1–6.
80. Vera H, John G, Paul M, Christian M, Rodryg R, Joseph E. Phase II study of two dose schedules of C.E.R.A (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. *Trials*. 2007; 8:8.

